Compare Dow Inc (DOW) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Mesoblast Limited — how do they compare? Dow Inc trades at $28.5 (market cap $20.65B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Dow Inc is far larger — about 11.8× Mesoblast Limited's market cap, and Dow Inc pays a 4.9% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and Mesoblast Limited for 14 Days on average.
| DOW | MESO | |
|---|---|---|
Market Cap | $20.65B | $1.75B |
Volume | 14,126,943 | 239,027 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $20.96 |
52-Week Low | $20.65 | $13.19 |
Typical Hold Time | 82 Days | 14 Days |
Enterprise Value | $36.34B | $1.83B |
Dividend Yield | 4.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $27.77, down 1.38% with bearish technical signals. The company shows mixed fundamentals with negative net income margin of -3.13% and ROE of -7.86%, though recent earnings have beaten expectations. Cash flow trends show operational improvement from $1.03B in 2025 to projected $3.9B in 2026. Analyst consensus is mixed with 27.8% buy ratings and a $34.22 price target, representing 23% upside potential.
While DOW faces margin pressures and declining revenue, the stock trades at attractive valuation multiples with P/S of 0.48. The dividend remains intact with $0.35 payment scheduled for September 2026. Key risks include ongoing profitability challenges and chemical sector headwinds, but earnings beats and cash flow improvement provide potential catalysts for patient investors.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
